1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
- Resource Type
- Source
- Annals of Oncology. 32:S1172-S1173
- Subject
Oncology medicine.medical_specialty business.industry T cell Anti pd 1 Half-life Hematology medicine.anatomical_structure Internal medicine Medicine In patient Non small cell business - Language
- ISSN
- 0923-7534